2021
DOI: 10.18553/jmcp.2021.27.8.1129
|View full text |Cite
|
Sign up to set email alerts
|

Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
15
0
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(17 citation statements)
references
References 16 publications
1
15
0
1
Order By: Relevance
“…In addition, first-to-market products may be favored due to provider prescribing habits as well as negotiated discounts (e.g. through preferred placement on formularies or favorable rates negotiated by PBMs) [40,41]. These factors may increase the plans' willingness to offer non-restrictive coverage.…”
Section: Discussionmentioning
confidence: 99%
“…In addition, first-to-market products may be favored due to provider prescribing habits as well as negotiated discounts (e.g. through preferred placement on formularies or favorable rates negotiated by PBMs) [40,41]. These factors may increase the plans' willingness to offer non-restrictive coverage.…”
Section: Discussionmentioning
confidence: 99%
“…More recent evidence from a payer-provider focus group similarly proposed greater biosimilar education as a means to increase biosimilar use. 20 Patient support programs for certain biologic therapies -including patient education, home delivery and nursing services -typically paid for by manufacturers also contribute to the total value of biologic therapies. 5…”
Section: Patient and Provider Supportmentioning
confidence: 99%
“…Les études incluses dans cette revue évoquaient un manque de connaissances sur les biosimilaires et concluaient que la prescription des biosimilaires allait être favorisée par le temps et l'expérience acquise avec ces agents. Des données plus récentes provenant d'un groupe de discussion regroupant des régimes payeurs et des professionnels de la santé ont également proposé une meilleure sensibilisation aux biosimilaires comme moyen de promouvoir leur utilisation 20 . Les programmes de soutien aux patients offerts et généralement défrayés par les fabricants de certains agents biologiques, incluant l'enseignement, la livraison à domicile et des services de soins infirmiers, sont une valeur ajoutée pour les traitements biologiques 5 .…”
Section: Soutien Aux Patients Et Aux Professionnels De La Santéunclassified